PeopleLinx reels in $3.5 mln

Philadelphia-based PeopleLinx, which provides solutions that improve buyer engagement, has raised $3.5 million in funding. The investors were Osage Venture Partners, Greycroft Partners and MissionOG.

Osage University Partners adds to team

Osage University Partners has hired Kirsten Leute as senior vice president of university relations. Previously, Leute worked at Stanford University where she served as an associate director of the office of technology licensing.

129 Views

Picwell snaps up more than $4 mln Series A

Picwell, a predictive recommendation engine provider for health plan section, has secured more than $4 million in Series A funding. MassMutual Ventures led the round with participation from other investors that included Osage University Partners.

148 Views

Menlo Security attracts $25 mln Series B

Menlo Park, California-based Menlo Security, a cyber security company that has launched from stealth mode, has raised $25 million in Series B funding. Sutter Hill Ventures led the round with participation from return backers General Catalyst, Osage University Partners and Engineering Capital.

122 Views

Clarifai nets $10 mln Series A

New York City-based Clarifai, a provider of image recognition technology, has raised an overall total of $10 million in Series A funding, the company announced in a blog post on its site. Union Square Ventures, Lux Capital and Osage University Partners led the round with participation from Google Ventures, Qualcomm Ventures, Nvidia Ventures, Corazon Capital, LDV Capital and New York University.

 

Seismos pulls in $4 mln

Austin, Texas-based Seismos Inc, a provider of real-time subsurface fluid flow monitoring for oil and gas production optimization, has received about $4 million in funding. Javelin Venture Partners led the round with participation from other investors that included Osage University Partners. Also, Noah Doyle, a general partner at Javelin Venture Partners, has been added to the Seismos board of directors.

Merganser Biotech snags $28 mln Series A

Merganser Biotech Inc, which focuses on treating rare blood and iron-related diseases, has secured $28 million in Series A financing. Novartis Venture Fund led the round with participation from Frazier Healthcare, Sutter Hill Ventures, Osage University Partners, BioAdvance and Stateside Developments. In addition to the funding, Markus Goebel of Novartis Venture Fund, James Topper of Frazier Healthcare and Jeffrey Bird of Sutter Hill Ventures have been added to Merganser’s board of directors. Also, Bill Harrington of Osage University Partners has been named as a board observer.

PMV Pharmaceuticals grabs $30 mln

PMV Pharmaceuticals, which develops p53 targeted small molecule drugs to treat cancer, has raised $30 million in Series A financing. OrbiMed led the round with participation from Osage University Partners and supported by founding investor InterWest Partners. In addition to the funding, Dr. Peter Thompson of OrbiMed has been appointed to PMV’s board of directors.

280 Views

Menlo Security attracts $10.5 mln Series A

Menlo Park, Calif.-based Menlo Security, a stealth cyber security start-up, has secured $10.5 million in Series A funding. General Catalyst Partners led the round with participation from Osage University Partners. In conjunction with the funding, Steve Herrod, a managing director at General Catalyst, has been added to Menlo Security’s board.

162 Views

3D firm Paracosm attracts $3.3 mln seed

3D firm Paracosm has closed $3.3 million in seed funding. Atlas Venture led the round with participation from other investors that included iRobot, Osage University Partners, BOLDstart Ventures, New World Angels and Deep Fork Capital.

302 Views

Liquid Light closes $15 mln Series B funding round

Liquid Light, which develops and licenses process technology to make major chemicals from carbon dioxide, has raised a $15 million Series B funding round. New investors in the funding include Sustainable Conversion Ventures. Existing investors include VantagePoint Capital Partners, BP Ventures, Chrysalix Energy Venture Capital and Osage University Partners.

Otonomy scores $49 mln Series D funds

Otonomy said Wednesday that it has closed $49 million in Series D funding. The investors included Perceptive Advisors, Federated Kaufmann Funds, OrbiMed Advisors, Novo Ventures, TPG Biotech, Avalon Ventures, Domain Associates, RiverVest Venture Partners, Aperture Venture Partners and Osage University Partners. Based in San Diego, Calif., Otonomy is a biopharmaceutical company that develops treatments for ear disorders and diseases.

VC-backed Liquid Light adds Bayer veteran to executive team

Liquid Light has hired Dave Law as executive vice president of operations. Previously, Law worked at Bayer. Liquid Light is a provider of process technology that makes major chemicals from carbon dioxide. Its backers include VantagePoint Capital Partners, BP Ventures, Chrysalix Energy Venture Capital and Osage University Partners.

Kolltan Pharmaceuticals rakes in $60 mln

Kolltan Pharmaceuticals said Wednesday that it has secured $60 million in Series D financing. The investors included KLP Enterprises, Deerfield Management, HBM Healthcare Investments Ltd., Purdue Pharma and Osage University Partners. Based in New Haven, Conn., Kolltan Pharmaceuticals is a biopharmaceutical company that targets receptor tyrosine kinases.

Kymeta Closes $50m Series C

Kymeta Corporation has closed a $50 million Series C financing to accelerate the company’s growth plans. Kymeta designs and manufactures satellite communication antennas and systems. Existing Kymeta investors including Bill Gates, Lux Capital and Liberty Global were joined in the financing by Osage University Partners and The Kresge Foundation.

eFFECTOR Therapeutics Raises $45 Million Series A

Biopharmaceutical company eFFECTOR Therapeutics has completed a $45 million Series A financing. Investors include U.S. Venture Partners, Abingworth, Novartis Venture Funds, SR One, Astellas Venture Management, Osage University Partners and Mission Bay Capital.

Cardioxyl Raises Series B Led By OrbiMed

Cardioxyl Pharmaceuticals has secured $28 million in a Series B financing led by OrbiMed Advisors. New investor Osage University Partners joined OrbiMed and returning investors New Enterprise Associates and The Aurora Funds in the financing.

PE HUB Community

Join the 12523 members of PE HUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

PE HUB News Briefs

RSS Feed Widget